|Year : 2020 | Volume
| Issue : 3 | Page : 111-114
Addressing challenges due to the COVID-19 pandemic – A site and investigator perspective
Priya Ranganathan1, Deepa Nair1, Nithya Jaideep Gogtay2
1 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
2 Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
|Date of Submission||02-Jun-2020|
|Date of Acceptance||03-Jun-2020|
|Date of Web Publication||6-Jul-2020|
Dr. Nithya Jaideep Gogtay
Seth GS Medical College and KEM Hospital, Parel, Mumbai - 400 012, Maharashtra
Source of Support: None, Conflict of Interest: None
| Abstract|| |
The coronavirus disease-19 pandemic has affected all aspects of health care including clinical research, as the focus of health-care systems has shifted to maintaining essential care. The impact on clinical research has been profound. In this article, we have enlisted the multiple challenges faced by investigators and sites in carrying out clinical research activities during this crisis and the steps which can be taken by them to reduce the impact of this evolving pandemic on clinical research.
Keywords: Challenges, clinical research, pandemic
|How to cite this article:|
Ranganathan P, Nair D, Gogtay NJ. Addressing challenges due to the COVID-19 pandemic – A site and investigator perspective. Perspect Clin Res 2020;11:111-4
|How to cite this URL:|
Ranganathan P, Nair D, Gogtay NJ. Addressing challenges due to the COVID-19 pandemic – A site and investigator perspective. Perspect Clin Res [serial online] 2020 [cited 2020 Oct 1];11:111-4. Available from: http://www.picronline.org/text.asp?2020/11/3/111/288953
| Introduction|| |
The current coronavirus disease (COVID-19) pandemic has affected 215 countries across the world, infecting nearly 5.5 million people and causing over 3 lakh deaths. The impact of the pandemic has been catastrophic, affecting individuals, populations, and systems at multiple levels. The focus of health care has shifted to provision of patient care while fields like education and research have taken a back seat. In this article, we examine the impact of the pandemic on clinical research activities at institutes and identify measures that can be taken to address research activities within the existing constraints, even as the pandemic continues to evolve.
| Measures Taken to Mitigate the Impact of the Pandemic|| |
Most countries have imposed various degrees of lockdown, leading to restrictions on the movement of individuals. This has been in an attempt to flatten the curve so as to get the health system in readiness for patient care.
Considering that hospitals are likely to be hotspots of infection and to decrease crowds, patients have been asked to avoid all nonessential hospital visits. Most hospitals have curtailed outpatient appointments and have replaced them with telephonic or videoconferencing alternatives. In addition, the working patterns of hospital staff have changed dramatically. First, the workforce has been decreased – partly as a deliberate measure – to allow social distancing, to minimize the number of health-care workers getting exposed at any point, and to allow periods of rest to prevent fatigue and burnout in a stressful situation, but also in part unplanned – due to logistics of travel and inability to reach the workplace or due to staff being unwell or quarantined. Second, there has been restructuring of staff within hospitals so that research and other support staff can help with the maintenance of essential clinical services. Third, diagnostic facilities such as imaging and laboratory services have minimized nonurgent testing.
| Impact on Patients and Participants|| |
The overall impact of these measures on clinical research is that patients are unwilling and/or unable to visit hospitals, and even if they do, the available infrastructure is not able to support research activities. The limitations on movement and transport have also affected other aspects of research – for example, investigational products (IPs) cannot be delivered to research sites and sponsor or contract research organization (CRO) teams cannot conduct monitoring or other site visits.
| Guidelines to Address Conduct of Clinical Research during an Outbreak|| |
Several organizations such as the United States Food and Drug Administration, the European Medicines Agency, and, closer home, the Indian Council of Medical Research have issued guidelines to deal with deviations and modifications to research activities.,, The key message from these guidelines is that for any ongoing or new research during the pandemic, participant safety is paramount, adherence to good clinical practice is essential, and that integrity of study data must be protected.
[Table 1] enumerates the challenges faced by different stakeholders in the clinical research process during this pandemic. In this article, we specifically focus on how investigators and clinical research sites can address research activities in this situation.
|Table 1: Challenges faced by clinical research stakeholders during the coronavirus disease-19 pandemic|
Click here to view
| Site and Investigator Responses during the COVID Pandemic|| |
These are some of the measures which can be instituted during the pandemic to facilitate research activities.
Postponement of new studies and changes in ongoing studies
Sites must consider postponing the initiation of new trials and withholding recruitment on ongoing trials to the extent possible. For participants in ongoing studies, investigators must make a benefit–risk assessment for the individual patient and see if the trial medication can be delivered to the patient, a family physician locally available can give the medication, or if a local nursing home may be willing to treat the patient. For life-threatening conditions or when the trial is the only way the patient can access the medicine, every attempt must be made to help the patient. For example, one of the authors (NG) has an ongoing trial in animal bites where completing all doses of the vaccination is crucial as rabies is a disease that is 100% fatal. On the other hand, in oncology, because the outcomes of COVID may be worse in immune-suppressed individuals, the investigator can take a call on either going ahead with the study treatment or deferring it, particularly when the treatment can lead to an immunosuppressed state (trials involving high-dose steroids or immune checkpoint inhibitors) and therefore expose the patient to greater risk. After discussion with the sponsor, less essential blood draws and nonessential visits can be done away altogether to ease the burden on both the investigator and patient.
For each ongoing trial, the investigator must identify essential and nonessential aspects. Of these, the nonessential aspects (e.g., routine site visits or monitoring) can be delayed. For essential aspects, such as response assessments or laboratory tests, alternate methods need to be established. For example, one could adopt virtual or telephonic assessments or authorize laboratories and centers close to the participants' residence to facilitate testing and response evaluation. If an in-person visit to the site is deemed mandatory, precautions should be taken to minimize the risks to participants. Participants who are considered high risk for COVID complications (elderly and those with comorbidities) should be excluded. The timing of the study visit can be modified to coincide with a visit for routine clinical care. There should be a separate waiting room for research patients. Hospital entrances, waiting rooms, and pathways should be clearly demarcated so that research subjects do not interact with potentially infected patients.
Challenges with investigational products
There may be issues with access to IPs. Sponsors can use emergency courier services to arrange delivery of high-priority research medications to sites. Direct shipping to participants can be considered to circumvent the need for site visits. To decrease the frequency of visits, larger quantities of IP can be issued at each visit.
Addressing protocol deviations and violations and serious adverse events
Because participants are likely to have delayed or missed visits and assessments, protocol violations will increase. These need to be informed to the institutional review board (IRB). Investigators should have a dialog with the IRBs to address these and follow revised IRB standard operating procedures on protocol deviations and violations. Various changes in the protocol and the possibility of infection with COVID may alter the risk–benefit to participants, which necessitates changes in the informed consent. This new information needs to be shared with participants telephonically and documented in the source files. For regulatory studies, investigators and sponsors can discuss with regulatory authorities for flexibility in conducting/completing the study. Site personnel can be given remote access to electronic medical records to enable them to complete study-related documentation. Reporting of serious adverse events should continue as per standard requirements. In addition, if the study participants develop COVID, this should be reported to the sponsor and the ethics committee, and causality (relatedness to study intervention) should be determined. This is essential as some interventions may increase the susceptibility of the participant to COVID.
The changes listed above may necessitate additional research funding. In addition, slow accrual will result in prolongation of study duration. This needs to be intimated to and approved by the IRB. Similarly, reimbursement for study-related expenses may be delayed – investigators should prioritize this to avoid inconveniencing participants. They should also establish communication with sponsors for funded studies to find pragmatic solutions to accrual and funding. For multicentric studies, sponsors can come up with a central plan of modifications to the trial so as to keep all centers on the same page.
Addressing psychological impact
Investigators need to consider the psychological impact of the pandemic on research participants. While they may be anxious about COVID and its consequences, there may also be concerns about interruptions in study treatments or assessments. Investigators should be available to allay these fears and to provide risk-stratified options to individual research subjects for continuing research participation during this period. Finally, as the pandemic recedes, there should be caution in re-starting studies as a second wave of infection is very likely.
In summary, the COVID pandemic has created an unprecedented situation, which is likely to negatively impact the conduct of clinical research. The various stakeholders in the clinical research process need to work out strategies to ensure that research activities are maintained as much as possible, and that the safety of participants and integrity of research data is not compromised.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Pramesh CS, Badwe RA. Cancer management in India during Covid-19. N
Engl J Med 2020;382:e61.
Fleming TR, Labriola D, Wittes J. Conducting clinical research during the COVID-19 pandemic: Protecting scientific integrity. JAMA 2020. doi: 10.1001/jama.2020.9286.